Sulindac-d3
(Synonyms: MK-231-d3) 目录号 : GC48677
An internal standard for the quantification of sulindac
Cas No.:38194-50-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Sulindac-d3 is intended for use as an internal standard for the quantification of sulindac by GC- or LC-MS. Sulindac is a non-steroidal anti-inflammatory drug (NSAID), selective COX-2 inhibitor (IC50s = 0.79 and >1,000 µM for COX-2 and COX-1, respectively), and prodrug form of sulindac sulfide .1,2,3,4 Sulindac is reduced by intestinal bacteria to form sulindac sulfide.1 It inhibits acetic acid-induced writhing in mice and reduces paw edema induced by carrageenan in rats when administered at a dose of 100 mg/kg.3 Sulindac (60 mg/kg) reduces tumor growth in MiaPaCa-2 and BxPC-3 mouse xenograft models.4 Formulations containing sulindac have been used in the treatment of pain associated with arthritis, ankylosing spondylitis, and gout.
1.Maseda, D., and Ricciotti, E.NSAID-gut microbiota interactionsFront. Pharmacol.111153(2020) 2.Grossman, C.J., Wiseman, J., Lucas, F.S., et al.Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox 2 inhibitorsInflamm. Res.44(6)253-257(1995) 3.Bhat, M.A., Al-Omar, M.A., Alsaif, N.A., et al.Novel sulindac derivatives: Synthesis, characterisation, evaluation of antioxidant, analgesic, anti-inflammatory, ulcerogenic and COX-2 inhibition activityJ. Enzyme Inhib. Med. Chem.35(1)921-934(2020) 4.Yip-Schneider, M.T., Wu, H., Ralstin, M., et al.Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivoMol. Cancer Ther.6(6)1736-1744(2007)
| Cas No. | 38194-50-2 | SDF | |
| 别名 | MK-231-d3 | ||
| Canonical SMILES | OC(CC1=C(C)/C(C2=CC=C(F)C=C21)=C/C3=CC=C(C=C3)S(C([2H])([2H])[2H])=O)=O | ||
| 分子式 | C20H14D3FO3S | 分子量 | 359.4 |
| 溶解度 | DMSO : 50 mg/mL (140.29 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble) | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7824 mL | 13.9121 mL | 27.8242 mL |
| 5 mM | 0.5565 mL | 2.7824 mL | 5.5648 mL |
| 10 mM | 0.2782 mL | 1.3912 mL | 2.7824 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。